AAAAAA
Results: 1-25/38
Authors:
Zore, I
Krasovec, M
Cimerman, N
Kuhelj, R
Werle, B
Nielsen, HJ
Brunner, N
Kos, J
Citation: I. Zore et al., Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer, BIOL CHEM, 382(5), 2001, pp. 805-810
Authors:
Fernebro, E
Madsen, RR
Ferno, M
Brunner, N
Bendahl, PO
Christensen, IJ
Johnson, A
Nilbert, M
Citation: E. Fernebro et al., Prognostic importance of the soluble plasminogen activator receptor; suPAR, in plasma from rectal cancer patients, EUR J CANC, 37(4), 2001, pp. 486-491
Authors:
Fredstorp-Lidebring, M
Bendahl, PO
Brunner, N
Casslen, B
Hogberg, T
Langstrom-Einarsson, E
Willen, R
Ferno, M
Citation: M. Fredstorp-lidebring et al., Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer, EUR J CANC, 37(18), 2001, pp. 2339-2348
Authors:
Ohlsson, H
Brunner, N
Engelholm, LH
Lundholt, BK
Weidle, U
Briand, P
Lykkesfeldt, AE
Citation: H. Ohlsson et al., Identification of two estrogen regulated genes associated with growth regulation of human breast cancer, MOL C ENDOC, 182(1), 2001, pp. 1-11
Authors:
Holst-Hansen, C
Low, JA
Stephens, RW
Johnson, MD
Carmeliet, P
Frandsen, TL
Brunner, N
Dickson, RB
Citation: C. Holst-hansen et al., Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat, BREAST CANC, 68(3), 2001, pp. 225-237
Authors:
Riisbro, R
Stephens, RW
Brunner, N
Christensen, IJ
Nielsen, HJ
Heilmann, L
von Tempelhoff, GF
Citation: R. Riisbro et al., Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases, GYNECOL ONC, 82(3), 2001, pp. 523-531
Authors:
Nielsen, HJ
Mortensen, T
Holten-Andersen, M
Brunner, N
Sorensen, S
Rask-Madsen, J
Citation: Hj. Nielsen et al., Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohndisease, SC J GASTR, 36(3), 2001, pp. 265-269
Authors:
Bajou, K
Masson, V
Gerard, RD
Schmitt, PM
Albert, V
Praus, M
Lund, LR
Frandsen, TL
Brunner, N
Dano, K
Fusenig, NE
Weidle, U
Carmeliet, G
Loskutoff, D
Collen, D
Carmeliet, P
Foidart, JM
Noel, AS
Citation: K. Bajou et al., The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies, J CELL BIOL, 152(4), 2001, pp. 777-784
Authors:
Frandsen, TL
Holst-Hansen, C
Nielsen, BS
Christensen, IJ
Nyengaard, JR
Carmeliet, P
Brunner, N
Citation: Tl. Frandsen et al., Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) fin the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model, CANCER RES, 61(2), 2001, pp. 532-537
Authors:
de Witte, JH
Foekens, JA
Brunner, N
Heuvel, JJTM
van Tienoven, TH
Look, MP
Klijn, JGM
Geurts-Moespot, A
Grebenchtchikov, N
Benraad, TJ
Sweep, CGJ
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours, BR J CANC, 85(1), 2001, pp. 85-92
Authors:
Brunner, N
Citation: N. Brunner, Maximal ideals and the axiom of choice, UNSOLVED PROBLEMS ON MATHEMATICS FOR THE 21ST CENTURY, 2001, pp. 183-192
Authors:
Kos, J
Krasovec, M
Cimerman, N
Nielsen, HJ
Christensen, IJ
Brunner, N
Citation: J. Kos et al., Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: Relation to prognosis, CLIN CANC R, 6(2), 2000, pp. 505-511
Authors:
Holten-Andersen, MN
Stephens, RW
Nielsen, HJ
Murphy, G
Christensen, IJ
Stetler-Stevenson, W
Brunner, N
Citation: Mn. Holten-andersen et al., High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, CLIN CANC R, 6(11), 2000, pp. 4292-4299
Authors:
Nielsen, HJ
Christensen, IJ
Sorensen, S
Moesgaard, F
Brunner, N
Citation: Hj. Nielsen et al., Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer, ANN SURG O, 7(8), 2000, pp. 617-623
Authors:
Werther, K
Christensen, IJ
Brunner, N
Nielsen, HJ
Citation: K. Werther et al., Soluble vascular endothelial growth factor levels in patients with primarycolorectal carcinoma, EUR J SUR O, 26(7), 2000, pp. 657-662
Authors:
Malmstrom, P
Bendahl, PO
Boiesen, P
Brunner, N
Idvall, I
Ferno, M
Citation: P. Malmstrom et al., S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic gradein a prospective study of premenopausal lymph node-negative breast cancer, J CL ONCOL, 19(7), 2000, pp. 2010-2019
Authors:
Kos, J
Werle, B
Lah, T
Brunner, N
Citation: J. Kos et al., Cysteine proteinases and their inhibitors in extracellular fluids: Markersfor diagnosis and prognosis in cancer, INT J B MAR, 15(1), 2000, pp. 84-89
Authors:
Holst-Hansen, C
Stephens, RW
Johannessen, BE
Jensen, PB
Brunner, N
Citation: C. Holst-hansen et al., Plasma Escherichia coli beta-galactosidase as a marker of tumor burden andresponse to experimental anti-neoplastic therapy in nude mice xenografted with lacZ transduced human tumor cells, LAB INV, 80(5), 2000, pp. 719-724
Authors:
Werther, K
Normark, M
Hansen, BF
Brunner, N
Nielsen, HJ
Citation: K. Werther et al., The use of the 33CELLection Kit (TM) in the isolation of carcinoma cells from mononuclear cell suspensions, J IMMUNOL M, 238(1-2), 2000, pp. 133-141
Authors:
Hoyer-Hansen, G
Hamers, MJAG
Pedersen, AN
Nielsen, HJ
Brunner, N
Dano, K
Stephens, RW
Citation: G. Hoyer-hansen et al., Loss of ELISA specificity due to biotinylation of monoclonal antibodies, J IMMUNOL M, 235(1-2), 2000, pp. 91-99
Authors:
Foekens, JA
Peters, HA
Look, MP
Portengen, H
Schmitt, M
Kramer, MD
Brunner, N
Janicke, F
Meijer-van Gelder, ME
Henzen-Logmans, SC
van Putten, WLJ
Klijn, JGM
Citation: Ja. Foekens et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, CANCER RES, 60(3), 2000, pp. 636-643
Authors:
Pedersen, AN
Christensen, IJ
Stephens, RW
Briand, P
Mouridsen, HT
Dano, K
Brunner, N
Citation: An. Pedersen et al., The complex between urokinase and its type-1 inhibitor in primary breast cancer: Relation to survival, CANCER RES, 60(24), 2000, pp. 6927-6934
Authors:
Slot, O
Brunner, N
Stephens, RW
Citation: O. Slot et al., Marker of erosive progression in RA, ANN RHEUM D, 59(8), 2000, pp. 656-656
Authors:
Stephens, RW
Nielsen, HJ
Christensen, IJ
Thorlacius-Ussing, O
Sorensen, S
Dano, K
Brunner, N
Citation: Rw. Stephens et al., Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis, J NAT CANC, 91(10), 1999, pp. 869-874
Authors:
Brunner, N
Nielsen, HJ
Hamers, M
Christensen, IJ
Thorlacius-Ussing, O
Stephens, RW
Citation: N. Brunner et al., The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer, APMIS, 107(1), 1999, pp. 160-167